Adamis Pharmaceuticals Corp (ADMP)

[tdeck]

IMHO at this point this company/stock is at its most investable time at a price that is at its best price point not only for short term appreciation but long term growth long into 2020, and I say that with 100% conviction the numbers speak for themselves.

The nature of "trading" and the large groups that play stocks with no idea whatsoever as to the fundamentals of a accompany just what they can push and hustle from their own distorted misrepresentations of the realities, has made this IMHO one of the bet investments for return in the biotech sector, bar none.

The company was valued far above the current market cap when the thoughts that down the rod they would have their US Compounding business reaching profitability which is in the near term now. The thoughts of having Symjepi and a major player on the space as a partner with Novartis subsidiary Sandoz. That the company would have revenues rising QoQ and YoY with those numbers set to jump dramatically with the commercial launch of Symjepi. Finally is was being value more when Zhimi was just a thought of being which is just about to hopefully be reality.

With all of those things realized how can it be valued what it is? Not for long regardless of Zhimi pdufa which in the current opioid overdoes climate and the push for more powerful opioid inhibitors. The game is getting ready to change and all the nonsense is getting ready to come to a halt, bare minimum let the revs jump even double the $900K+ they have been jumping this Q, triple quadruple, well those who have been playing the short game will find themselves in a rather precarious position, I will enjoy such an outcome.


From the Q2 CC...……….

Sandoz has publicly stated that effective immediately (July 9th), over 60% of commercially insured people in the U.S. now have access to SYMJEPI through national and regional payers. The Symjepi also being a lower cost alternative to expensive auto-injectors. These formulary additions demonstrate Sandoz's commitment to improving patient access from life saving medicines like SYMJEPI. Additionally, we believe that Sandoz has doing extensive marketing campaign and they will be visible in major scientific journals, as well as via press, such as USA Today and the New York Times. Back to school ephedrine sales are 3

Although, it is certainly not reflected in our low share price, I believe Adamis has never been more valuable. I will repeat that, never more valuable. With the potential upside of SYMJEPI and US Compounding reaching breakeven on the cash flow basis, as well as the possibility for receiving our third product approval in three years for ZIMHI, I still believe 2019 will be a great year for our company. I never once thought that we would not exceed. I believe our obstacles will eventually be turned into our successes.

First, the second quarter revenue grew 70.5% over the first quarter, approximately $5.8 million and $4.9 million respectively and 47% over the second quarter of 2018. This increase was attributable through the continued growth of US Compounding and manufacturing revenue related to the non-retail launch of SYMJEPI.

Gross profit for the second quarter grew 64% in the first quarter, approximately $2.1 million and $1.3 million respectively, and grew 37.6% over the second quarter of 2018. This increase was attributable through the limited launch of SYMJEPI, and increasing margins at US Compounding.

I would now like to update everyone on the clinical progress of our high dose naloxone injection product known as ZIMHI. As a reminder, naloxone is an opiate antagonist and is considered the drug of choice for immediate administration to treat opiate overdoses. As you know, the accidental opioid overdoses have become a public health crisis to the United States, with the number of deaths due to opiates increasing fivefold since 1999.

Importantly, the largest and fastest growing component of this high rate of mortality are due to the potent synthetic opiates, such as fentanyl. We believe that this dramatic increase in the [use] of synthetic opiates currently a brief approved dose to naloxone maybe inadequate. That is why we believe there's a public health need for our high dose ZIMHI product candidate.

Q&A From CC

Lucas Lee

This is Lucas Lee on for Elliot Wilbur. Congrats on the quarter, and I have a few questions that I would like ask. First one is on SYMJEPI. I see that SYMJEPI sales have doubled sequentially. Can you give us more color on the progress of the launch since Sandoz made the expanded launch announcement in early July?

David Marguglio

This is David. I'll take that. Obviously, with just a few weeks passing since the launch, it's very early for us to make any sort of judgment. But the activity that we can see our with regard to marketing and commercialization efforts by Sandoz, we feel very confident and in the current trajectory. And so we would expect to see an increasing growth curve for that product now that it's launched into the majority of market.

And although, we covered this, I think to some degree on the prior call, I'll go ahead and reiterate that the beginning of this phased launch that occurred earlier in the year only focused on the institutional market, which represents about 15%, one-five, of the overall market. Also, was exclusively with the 0.3 milligram dose. So now with the full launch that occurred in July that opens up, obviously, the other 85% of the market, as well as bringing on the second dose. So we think that the really jumping off point for this product started in the beginning of July.

Lucas Lee

Next one is on US Compounding division. I see that the revenues are improving sequentially. How should we think about this revenue trend in the second half of 2019? Do you think this division could help slowing the cash burn for the parent company?

Rob Hopkins

This is Rob Hopkins. Yes, that's the anticipation for the second half that US Compounding would begin to contribute back to the parent cash.

Jason Kolbert

I was trying to get a handle on the recorded sales and the proportions of where you are in the professional market. And I'm assuming that we really haven't seen at all the impact of the retail market, which could be quite significant. And I'd also like to dovetail onto that. How -- as a competition heats up and the epi market? How -- where is pricing today? Because depending on where I do a channel check, I get different number. So that would be very helpful, David.

David Marguglio

Sure. So the institutional market, as I've previously stated, is obviously a small slice of the overall market. But this is important because there's a lot of influencers within that market. And that market as it defers from the point of sale transactions that you see on the retail side, tend to be contracted and those contracts tend to take significant lead time. So the good news is once you're in, those contracts are established and those relationships are moving forward that there's a sizable amount, I guess, from each of those individual customers that can be expected as far as revenue. But the offset to that is that those relationships take some time to put in place.

So I think that is why the sales on an institutional side for the first -- not even Q4 quarters that we've seen have been a slow ramp. I think that we should expect to see a significant uptick on the institutional market. But as you alluded to, with retail being 85% of the market, even a slow ramp on the retail can quickly eclipse all the current sales on the institutional side.


Okay, so.

Now, don't get me wrong Zimhi is going to really exponentially increase the outlook for ADMP, no doubt, it will be huge. But, the company has already surpassed so many milestones and is now trading at such a discounted price because people are just missing the plot, its like all the manipulators, traders, shorts etc. are saying look over here, look over here, ignore all that cash rolling in look over here at this pile of shit nonsense we are trying to push. Light bulb getting ready to come on, watch. I am not going to say what it could be, but, anyone with a lick of sense looking at the numbers/growth of Q1 & Q2 and reading the questions and their answers can put 2 and 2 together, lets just say people are just missing the plot, they cannot forest for the trees as they say..


Q&A from CC on Zimhi

Lucas Lee

And lastly, can you give us little more update on ZIMHI. I want to hear how the discussions being going with the FDA. You also indicated that you're working towards finalizing the partnership prior to the approval. Could you give us more color on that? And also if approved, how quickly do you think the partner could launch the product? That will be it, thank you.

Ronald Moss

So, this is Dr. Moss. We continue to work with the FDA throughout the NDA process, which is fairly typical. So far we have been able to, I believe, satisfy their questions that they've asked. And we are really focused on providing them with the updated clinical study report on the new study by the end of September, it was the target date. So overall, things are going well with them. And they worked with us very diligently with our proposal to change the reference drug as noted in the kaléo negotiations.

David Marguglio

So this is David Marguglio. With respect to the partnering process, that is ongoing and those discussions are confidential. But the timing, as I've mentioned in my prepared comments, is targeting a resolution for our commercial plan prior to an approval for the product. The overall goal for that and doing so is to reduce the timeline to as short as possible with respect to the delta between approval and a launch.

Now you asked directly what that time line may look like. Unfortunately, that's going to be determined by our eventual commercial partner. But I can tell you that we are going to great lengths to ensure that it is significantly compressed over what we went through with SYMJEPI.


If you add or start a position as I always say don't slap that ask bid sit that thing let them dig their hole further its the retail shorts players messing with it now as hedges have already been covering, retail both long and short are always the last to see the writing on the wall. Retail shots always miss the switch and chasing a 10% short term downside miss a 100-300% upside, its in their nature.

Some of the commercial launch press and marketing.

July 10, 2019
https://snacksafely.com/2019/07/watch-how-to-use-symjepi-the-prefilled-epinephrine-syringe-now-available-in-pharmacies/

The next news video comes from a Consumer Reports segment it appeared across the country at all local tv stations as well as national CNN FOX CNBC etc.

August 19, 2019
https://abc7chicago.com/health/consumer-reports-low-cost-epinephrine-options/5477916/

October 2, 2019
https://www.wral.com/epipen-shortage-cheaper-options-are-available/18672123/

https://www.pharmacytimes.com/resource-centers/allergy/frustration-leads-to-new-epinephrine-injectors

https://www.allergicliving.com/2019/07/09/%EF%BB%BFsymjepi-epinephrine-syringe-rolls-mylan-shortage-persists/

https://www.fiercepharma.com/pharma/sandoz-adamis-bolster-symjepi-rollout-amid-mylan-s-epipen-supply-woes

https://www.pharmacytimes.com/publications/issue/2019/august2019/symjepi-offers-new-option-for-injectable-epinephrine

https://www.empr.com/home/news/symjepi-0-15mg-0-3mg-injections-now-available-for-anaphylaxis-treatment/

https://business.medicaldialogues.in/sandoz-launches-symjepi-injection-in-us-to-help-treat-allergic-reactions/

https://generics.pharmaintelligence.informa.com/GB140491/Sandoz-Seeks-Help-From-Doctors-For-US-Symjepi-Push

Could provide umpteen more links, but what's the point really you get it a full on media awareness happening has occurred and di starting the first week of July, tick tock.

Peace out.